Today DiaGenic received notice of allowance for its European family 2 patent application, 0377005.4. The claims allowed cover the use of number of important gene sequences in blood for diagnosis and monitoring of, among others, breast cancer and Alzheimer’s disease. The patent when granted will be valid until 2023. MD PhD Erik Christensen, managing director of DiaGenic comments, “The new European patent is an important milestone which strengthens our position in Europe. The company will now have a broad patent protection in the 27 European countries for both Alzheimer’s disease and Breast cancer. The company’s recently CE marked diagnostic tests for these diseases; ADtect® and BCtect®, have thus strong protection also in Europe”. Contact: MD PhD Erik Christensen, Managing Director Telephone: +47 95939918 e-mail:

About Us

NEL ASA is a leading global supplier of hydrogen technology for industrial / energy purposes, and has made over 500 deliveries in more than 50 countries. The company's main products are hydrogen production plants based on water electrolysis, complete hydrogen stations for transport and renewable energy storage solutions. The company has its roots from the hydrogen activities of Norsk Hydro, which dates back to 1927. The company also has a number of patents related to tests for early detection and diagnosis of diseases.